| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8235769 | International Journal of Radiation Oncology*Biology*Physics | 2009 | 7 Pages |
Abstract
Bortezomib administered at its typical “systemic” dose (1.3 mg/m2) is well tolerated and safe combined with temozolomide and radiotherapy when used in the treatment of central nervous system malignancies. A Phase II study to characterize efficacy is warranted.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Gregory J. M.D., Maria M.D., Mitchell M.D., Gayle A.D., Thomas M.D., Michael M.D., David M.D., Walter J. M.D., Adam P. M.D., Ph.D.,